Medigene AG: Medigene participates at four conferences in November 2018

Martinsried/Munich (pta/31.10.2018/07:30) MediGene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:

BIO-Europe 
Date: 5 - 7 November 2018
Location: Copenhagen, Denmark

SITC Annual Meeting 
Date: 7 - 11 November 2018
Location: Washington, USA

PEGS Europe 
Date: 13 - 17 November 2018
Location: Lisbon, Portugal

Jefferies Health Care Conference 
Date: 14 - 15 November 2018
Location: London, UK

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01, 
email: investor@medigene.com

emitter: Medigene AG, Lochhamer Stra├če 11, 82152 Planegg, Germany
contact person: Medigene PR/IR
e-mail: investor@medigene.com 
phone: +49 89 2000 33 3301
website: www.medigene.de 
ISIN(s): DE000A1X3W00
Exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate,

Back to news